Loading...
•
Jun 30, 2022
Eton Q2 2022 Earnings Report
Eton Pharmaceuticals reported financial results, divesting hospital products and focusing on rare diseases with strong Alkindi Sprinkle and Carglumic Acid sales.
Key Takeaways
Eton Pharmaceuticals reported a net sales increase to $7.4 million, driven by licensing payments and growth in ALKINDI SPRINKLE and Carglumic Acid tablets. The company is now focused on its rare disease strategy following the hospital products divestiture.
Net sales for the second quarter of 2022 were $7.4 million, compared to $3.1 million in the prior year period.
Product sales and royalty revenue were $2.4 million for the second quarter of 2022, compared to $0.6 million for the second quarter of 2021.
Gross profit for the second quarter of 2022 was $4.6 million, compared to $2.9 million in the prior year period.
Net loss for the second quarter of 2022 was $1.6 million, or $0.06 per basic and diluted share, compared to a loss of $2.0 million, or $0.08 per basic and diluted share in the prior year period.
Eton
Eton
Eton Revenue by Segment
Revenue by Segment
Product Sales & Royalties Revenue
CapyFin.com Forward Guidance
Eton Pharmaceuticals is progressing its R&D pipeline to support additional new product launches in coming years, including resubmitting the application for dehydrated alcohol injection and progressing development of ZENEO® hydrocortisone autoinjector.
Positive Outlook
- Resubmission of the application for dehydrated alcohol injection expected later this year, potentially allowing for approval and launch in 2023.
- Continued progress in the development of ZENEO® hydrocortisone autoinjector, with potential filing with the FDA in 2023.
- Initiation of development for two additional high-value rare disease products.
- Potential receipt of an additional $5.0 million milestone payment upon the launch of the recently approved Zonisade™ product.
- Focus on rare disease strategy following the divestiture of hospital products.